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Abstract. Lymphangiogenesis is involved in the dissemination 
of malignant cells from solid tumours to regional lymph nodes 
and possibly to various distant sites. Lymphangiogenesis is 
regulated by vascular endothelial growth factor (VEGF)-C 
and VEGF-D. Interleukin (IL)-24 is known as a cytokine 
with potent antitumour and tumour-suppressive activity which 
functions through its receptor (IL-22R). Expression of IL-24 
has been shown to be reduced in breast cancer, and the reduced 
expression is associated with lymphatic metastases and a poor 
prognosis. However, the involvement of IL-24 in lymphangio-
genesis during lymphatic metastasis remains unclear. The aim 
of the present study was to determine whether there is an asso-
ciation between IL-24, IL-22R and lymphangiogenic factors 
and markers in breast cancer. Analysis of IL-24, IL-22R and 
lymphangiogenic factors in malignant breast tissue samples 
(n=127) revealed a correlation between increased expres-
sion of lymphangiogenic markers (podoplanin, Prox-1 and 
LYVE-1) and reduced levels of IL-24 and IL-22R. Samples 
stained with a high degree of positivity for lymphangiogenic 
factors and markers whereas staining for IL-24 was weak. 
In vitro assays showed that the average perimeter length of 
microtubules formed by endothelial cells treated with IL-24 
was significantly reduced compared to the control. The growth 
of endothelial cells was significantly reduced when exposed 
to a high concentration of IL-24 (250 ng/ml). Treatment of 
HECV cells with IL-24 resulted in significantly reduced 
expression of VEGF-C (P<0.05) and VEGF-D (P<0.001). In 
conclusion, reduced expression of IL-24 and IL-22R in breast 
cancer is correlated with increased expression of specific 
lymphangiogenic markers. IL-24 suppressed in vitro growth 
and microtubule formation of endothelial cells. IL-24 may 
downregulate the expression of lymphangiogenic markers and 
factors although further research is required. This suggests 
that IL-24 plays a profound role in suppressing tumour 
lymphangiogenesis, thereby, reducing the likelihood of cancer 
metastasis via the lymphatic route.
Introduction
Lymphangiogenesis is the process by which new lymphatic 
vessels form from pre-existing lymphatic vessels or lymphatic 
endothelial progenitor cells (1). The process is important 
in the normal development of the lymphatic system and is 
also implicated in pathological processes such as inflamma-
tion, lymphedema and importantly cancer metastasis. The 
lymphatic vasculature serves as a major route for the dissemi-
nation of malignant cells from solid tumours, particularly to 
regional lymph nodes (2). The extent of lymph node metas-
tasis is a major determinant of both staging and prognosis in 
breast cancer.
The recent discovery of a number of molecular and cellular 
markers thought to be specific to lymphatic endothelial cells 
has enabled more detailed research into lymphangiogenesis. 
The most important lymphangiogenic markers include podo-
planin (a glomerular podocyte membrane mucoprotein) (3), 
Prox-1 (a homeobox gene involved in embryonic development 
of the lymphatic system) (4) and LYVE-1 (a marker shown to 
be found exclusively on lymphatic vessels in normal tissues 
and tumours) (5). Several studies have reported that high 
expression levels of lymphangiogenic markers (particularly 
podoplanin and LYVE-1) in breast tumours are correlated 
with increased lymphatic vessel density, increased likelihood 
of tumour metastasis to regional lymph nodes and therefore a 
poor prognosis (6-9).
The process of lymphangiogenesis is thought to be 
regulated by the interaction of vascular endothelial growth 
factor (VEGF)-C or VEGF-D with the cell surface receptor 
VEGFR-3 (2). Research suggests that VEGF-C expression in 
breast cancer may correlate with increased lymph node metas-
tases (10) and significantly poorer disease-free survival (assessed 
at five years) (11). In contrast, other studies have indicated that a 
high VEGF-C to VEGF-D ratio in breast tumours may be a 
more accurate predictor of increased likelihood of lymph node 
metastasis (12-14). High expression levels of lymphangiogenic 
factors or markers may be important in indicating an increased 
potential for lymphangiogenesis and cancer metastasis.
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Interleukin (IL)-24 is a member of the IL-10 cytokine 
family. The secreted protein is 206 amino acids in length 
and has a predicted size of 35-40 kDa (15). Previous studies 
suggest that IL-24 operates through interaction with IL-20R1/
IL-20R2 or IL-22R1/IL-20R2 heterodimers (15,16). IL-24 
was originally detected in human melanoma cells. However, 
it appears to be lowly expressed in cells of the immune 
system, including spleen cells, thymus cells and normal 
melanocytes (16).
IL-24 is thought to possess antitumour characteristics. By 
suppressing signals generated by tumour cells and through 
interference with tumour vasculature, IL-24 may act to inhibit 
tumour growth and metastasis (17). Forced expression of 
IL-24 in breast cancer cells was found to cause potent growth 
suppression (18). Results from in vitro assays suggest that 
IL-24 significantly reduces migration and motility of breast 
cancer cells (19).
Immunohistochemical staining has demonstrated that 
normal breast tissue contains substantially higher levels of 
IL-24 compared to malignant breast tissue. Lower transcript 
levels of IL-24 were found to be correlated with node-positive 
breast tumours, increased likelihood of distant metastasis, 
a poor prognosis and shorter disease-free survival. Patients 
with higher levels of IL-24 were more likely to have a 
better prognosis and remain alive and disease-free (19). The 
correlation between loss of IL-24 expression and increased 
tumour invasion may indicate that IL-24 has an important 
role in tumour suppression. However, how IL-24 is involved in 
lymphatic metastasis remains unclear.
The aim of the present study was to assess whether there 
is an association between levels of IL-24, IL-22R and the 
expression of lymphangiogenic factors and markers in breast 
cancer tissue samples obtained from a cohort of 127 women. 
In vitro studies were then carried out to investigate how IL-24 
alters the expression of lymphangiogenic factors and markers. 
The effect of IL-24 on specific functions (growth and micro-
tubule formation) of endothelial cells was also examined.
Materials and methods
Cohort of tissue samples. Breast cancer tissue samples (n=127) 
were collected from patients at the University Hospital of 
Wales, Cardiff. Ethical approval and informed consent was 
obtained. RNA extraction of the samples was performed using 
an RNA extraction kit (AbGene Ltd., Surrey, UK) along with 
reverse transcription. Pairs of PCR primers were designed 
using the Beacon Designer™ software and synthesised by 
Sigma-Aldrich. IcyclerIQ™ (Bio-Rad, Hemel Hempstead, 
UK) was used to carry out real-time quantitative PCR [based 
on previously described methods (19,20)] to detect transcript 
levels of IL-24, IL-22R and lymphangiogenic factors and 
markers in the breast cancer samples. The Amplifluor system 
(Intergen Inc., New York, NY, USA) was utilized under the 
following conditions: an initial period of 15 min at 95˚C 
followed by 60 cycles of 95˚C for 15 sec, 55˚C for 60 sec and 
72˚C for 20 sec together with QPCR Master Mix (ABgene, 
Surrey, UK).
Materials and cell lines. HECV cells purchased from Interlab 
(Milan, Italy) were maintained in Dulbecco's modified Eagle's 
medium (DMEM) (Sigma-Aldrich, Poole, UK) supplemented 
with benzylpenicillin, amphotericin B, streptomycin and 10% 
fetal bovine serum (Sigma-Aldrich). The cells were incu-
bated at 37˚C in 5% CO2 and 95% humidity until confluent. 
Matrigel (reconstituted basement membrane) was purchased 
from Collaborative Research Products (Bedford, MA, USA).
Treatment of cells with IL-24 and conventional and quanti-
tative polymerase chain reaction. Six 12.5-cm² tissue culture 
flasks were seeded with 1x106 HECV cells and incubated 
at 37˚C for 24 h. Cells were treated with 25 ng/ml human 
recombinant IL-24 (R&D Systems Europe) and incubated 
at 37˚C for 1, 2, 4 and 24 h. Total RNA reagent (TRI) was 
used to extract the RNA from IL-24-treated cells using 
the provided protocol (Sigma-Aldrich). RNA was quanti-
fied using a spectrophotometer (WPA UV 1101; Biotech 
Photometer, Cambridge, UK) and standardised to a concen-
tration of 500 ng. Reverse transcription was performed 
using the iScript cDNA synthesis kit (PrimerDesign Ltd., 
Southampton, UK).
Conventional PCR was carried out in a T-Cy Thermocycler 
(Creacon Technologies Ltd., The Netherlands) using REDTaq® 
ReadyMix™ PCR reaction mix (Sigma-Aldrich), cDNA from 
cells and the following primers: GAPDH (which served as a 
control), VEGF-C and VEGF-D (Table I). The reaction condi-
tions used were: 5 min at 94˚C, 40 sec at 94˚C, 40 sec at 55˚C, 
1 min at 72˚C for 35 cycles and 72˚C for 10 min. PCR products 
were then stained with SYBR Safe™ (Invitrogen) separated on 
a 1% agarose gel, visualised under UV light and photographed. 
ImageJ software was used to semi-quantify the results.
Real-time quantitative PCR was carried out using the 
iCycler iQ™ Real-Time detection system (Bio-Rad) to 
determine transcript levels of VEGF-C, VEGF-D and Prox-1 
in IL-24-treated HECV cells. QPCR was carried out in a 
96-well plate using a previously described method (21) with 
10 pmol sense primer, 1 pmol antisense Z primer (Table I) 
and 10 pmol FAM-probe, using a custom Hot-Start QPCR 
master mix, under the following conditions: 95˚C for 15 min, 
followed by 50 cycles at 95˚C for 15 sec, 55˚C for 4 sec and 
72˚C for 15 sec. The levels of transcripts were calculated as 
lymphangiogenic factor or lymphangiogenic marker/GAPDH 
ratio.
Western blotting. HECV cells (1x106) contained in 25 cm2 
flasks were treated with IL-24 (25 ng/ml) for 0, 1, 2 or 4 h. 
HMCSF buffer containing 1% Triton X-100, 2 mM CaCl2, 
100 µg/ml phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin, 
1 mg/ml aprotinin and 10 mM sodium orthovanadate was 
used to detach and lyse the cells. Insoluble components were 
then removed by rotating samples on a wheel for 1 h and 
centrifuging at 13,000 x g. The protein samples were blotted 
onto Hybond-C Extra nitrocellulose membranes (Amersham 
Biosciences UK Ltd., Bucks, UK). Protein expression of 
GAPDH and lymphangiogenic factors and markers in the 
samples were assessed. Antibodies specific to GAPDH, 
VEGF-C, LYVE-1 (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA, USA) and VEGF-D (R&D Systems Europe) were 
used. Visualisation of the protein bands was carried out using 
SuperSignal West Dura Extended Duration substrate chemi-
luminescent system (Perbio Science UK Ltd., Cramlington, 
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UK) and images were captured using a UVIprochem camera 
system (UVItec, Cambridge, UK).
The values shown graphically for QPCR, conventional 
PCR with semi-quantitative analysis and western blotting are 
expressed as the percentage of decrease in lymphangiogenic 
transcript expression compared to control cells (the expression 
in the cells not treated with IL-24 was regarded as baseline, 
i.e. having 100% lymphangiogenic factor/marker expression). 
The change in expression was shown as a percentage (%) in 
comparison with the control.
In vitro microtubule formation assay. The processes used 
were modified from previously published methods (22,23). 
Briefly, 96-well plates were coated with 100 µl/well of 
Matrigel (diluted in a 1 to 1 ratio with serum-free medium) 
and incubated for 60 min to allow the thin gel layer to set. 
HECV cells (3x104/well) were seeded onto the Matrigel layer. 
The cells were treated with IL-24 (2.5, 25 and 250 ng/ml) 
or a preparation of serum-free medium or normal medium 
and incubated for 4-6 h to allow tubule formation to occur. 
Subsequently, the microtubule lengths were visualized under 
bright light microscopy and quantified (total perimeter length 
per field) using ImageJ.
In vitro cell growth assay. The processes used were based on 
a previously published method (24). HECV cells (3,000/well) 
were plated into 96-well plates followed by treatment with 
IL-24 (2.5, 25 and 250 ng/ml) and a period of incubation 
(either overnight or 3 days). The cells were fixed in 4% 
formaldehyde and stained with 0.5% crystal violet. After 
washing, 10% acetic acid was added, and the absorbance was 
determined using a Bio-Tek ELx800 multiplate spectropho-
tometer (Bio-Tek Instruments Inc., Winooski, VT, USA) at a 
wavelength of 540 nm. Absorbance was used to represent the 
cell number.
Results
IL-24 and the expression of lymphangiogenic factors/markers 
in breast cancer. Following quantitative determination of 
the transcripts of IL-24, IL-22R, lymphangiogenic factors 
and markers in the breast cancer tissues (12,19), correlations 
among these factors were analysed.
Table II depicts the results where IL-24 and IL-22R 
are found in the presence of CK19 (a specific epithelial 
cell marker). Levels of IL-24 and IL-22R were therefore 
normalised values representative of those found within 
epithelial-derived malignant breast tissue. High levels of 
IL-22R were associated with significantly high levels of 
IL-24 expression (P<0.01). A significant correlation was 
evident between increased expression of LYVE-1 and reduced 
expression of IL-24 (correlation coefficient -0.288) (P<0.05) 
in the cohort of breast cancer tissue samples. Similarly, the 
expression of another lymphangiogenic marker, podoplanin, 
was also significantly inversely correlated with the expression 
of IL-24 (P<0.01) and IL-22R (P<0.05). Although the expres-
sion of other examined lymphangiogenic markers and factors 
(Prox-1, VEGFR-3 and VEGF-C) also appeared to increase 
in the tumours with lower expression of IL-24, no statisti-
cally significant correlation was noted. VEGF-D, however, 
a promoter of lymphangiogenesis tended to be positively 
associated with the expression of IL-24 (P=0.03).
Both epithelial-derived malignant breast tissue and 
surrounding stromal cells (including endothelial cells) are 
important factors in lymphangiogenesis of tumours. Therefore 
levels of IL-24 and IL-22R (non-normalised) in the cohort 
of breast cancer tissue samples are also provided in Table II. 
The expression of all lymphangiogenic factors (VEGF-C 
and VEGF-D) and lymphangiogenic markers (podoplanin, 
Prox-1, VEGFR-3 and LYVE-1) was inversely correlated with 
the expression of IL-24. In contrast VEGF-D, VEGF-C and 
Table I. Primer sequences.
Method Name Sequences
PCR VEGF-C F9 TTTGCCAATCACACTTCCTG
 VEGF-C R9 CAGGCACATTTTCCAGGATT
 VEGF-D F9 CAGGGCTGCTTCTAGTTTGG
 VEGF-D R9 TTCTTCAGGGATCTGGATGG
 GAPDH F8 ATGATATCGCCGCGCTCGTC
 GAPDH R8 GCTCGGTCAGGATCTTCA
QPCR VEGF-C F12 CTACAGATGTGGGGGTTGCT
 VEGF-C ZR12 ACTGAACCTGACCGTACAGTAGCTCGTGCTGGTGTTCA
 VEGF-D F12 TCCACATTGGAACGATCTGA
 VEGF-D ZR12 ACTGAACCTGACCGTACACTCCACAGCTTCCAGTCCTC
 Prox-1 F11 AGAGCAGGAAATGGCTGAAA
 Prox-1 ZR11 ACTGAACCTGACCGTACATCCGGTTGTAAGGAGTTTGG
 GAPDH F CTGAGTACGTCGTGGAGTC
 GAPDH ZR ACTGAACCTGACCGTACAGAGATGATGACCCTTTTG
F, forward; R, reverse; VEGF, vascular endothelial growth factor.
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VEGFR-3 (promoters of lymphangiogenesis) were positively 
associated with expression of IL-22R. None of the non-
normalised results was found to be significant.
Breast cancer tissue samples were immunohistochemi-
cally stained for levels of IL-24 and lymphangiogenic factors 
(VEGF-C and VEGF-D), IL-24 and lymphangiogenic markers 
Figure 1. Immunohistochemical staining of IL-24 and lymphangiogenic factors/markers in breast cancer specimens. (A) Breast cancer tissue samples were 
immunohistochemically stained for the presence of VEGF-C, VEGF-D and IL-24. Breast cancer cells stained positively for VEGF-C and VEGF-D but were 
virtually negative for the presence of IL-24. (B) Breast cancer tissue samples were immunohistochemically stained for the presence of Prox-1, podoplanin and 
IL-24. Breast cancer cells (arrowheads) and endothelial cells (arrows) stained positively for Prox-1 and podoplanin but were virtually negative for the presence 
of IL-24. Shown are the staining of different molecules in the matched specimens.
Table II. Correlations between IL-24/IL-22R and lymphangiogenic factors/markers at their transcript levels in breast cancer tissues.
Transcript name IL-24 IL-22R
VEGF-C -0.115 (P=0.358)/-0.047 (P=0.684) 0.108 (P=0.384)/0.120 (P=0.293)
VEGF-D 0.324 (P=0.03)/-0.068 (P=0.624) 0.289 (P=0.054)/0.105 (P=0.449)
Podoplanin -0.332 (P=0.001)/-0.183 (P=0.059) -0.260 (P=0.011)/-0.094 (P=0.33)
Prox-1 -0.199 (P=0.053)/-0.067 (P=0.486) -0.057 (P=0.578)/0.102 (P=0.291)
VEGR3 -0.156 (P=0.131)/-0.046 (P=0.637) -0.134 (P=0.192)/0.025 (P=0.792)
LYVE-1 -0.288 (P=0.017)/-0.161 (P=0.145) -0.039 (P=0.749)/-0.042 (P=0.707)
IL-22R 0.268 (P=0.008)/0.305 (P=0.001)
Correlation coefficient data comparing expression of lymphangiogenic factors/markers with expression of IL-24 and IL-22R in samples of 
breast cancer tissue. The correlation coefficient (P-value) of normalised transcript levels/the correlation coefficient (P-value) of non-normalised 
transcript levels are shown. Transcripts of each gene normalised against the corresponding CK19 levels, respectively, are shown as a ratio 
against CK19. VEGF, vascular endothelial growth factor.
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(Prox-1 and podoplanin). A high degree of VEGF-C and 
VEGF-D positivity was found to be present in breast cancer 
cells (Fig. 1). In comparison, endothelial cells contained 
within the tumour tissue did not stain positively for the 
lymphangiogenic factors VEGF-C and VEGF-D. Fig. 1 also 
shows that both cancer cells and endothelial cells stained with 
a high degree of positivity for the lymphangiogenic markers 
Prox-1 and podoplanin. Breast cancer cells appeared to 
contain low levels of IL-24 and therefore the staining for this 
cytokine was very weak or absent from the cancer cells.
Regulation of lymphangiogenic factors/markers in endo-
thelial cells by IL-24. Transcript levels of lymphangiogenic 
factors and markers in the IL-24-treated HECV cells were 
detected using conventional PCR with semi-quantitative 
analysis and QPCR. Conventional PCR with semi-quantitative 
analysis and QPCR demonstrated that treatment of HECV 
endothelial cells with IL-24 (at a concentration of 25 ng/ml) 
resulted in time-dependent downregulation of VEGF-C and 
VEGF-D over 24 h. Results obtained using both methods 
showed the highest levels of mRNA expression of VEGF-C 
and VEGF-D in the control cells (0 h). There was rapid and 
significant downregulation of VEGF-C after 1 h as detected 
using semi-quantitative PCR (P<0.05). This was followed by 
increased expression of VEGF-C after 2 h to levels almost 
equivalent to those detected in the control. A gradual decrease 
in expression of VEGF-C was then observed after 4 and 24 h 
of treatment. At 24 h significantly reduced levels of VEGF-C 
were detected using semi-quantitative PCR compared to the 
control (P<0.05) (Fig. 2A). QPCR results showed the same 
trend as those observed using semi-quantitative analysis. No 
QPCR results, however, were found to be significant, (Fig. 3B). 
In a same way, semi-quantitative analysis showed levels of 
expression of VEGF-D to be significantly reduced after 1 h of 
treatment with IL-24 (P<0.001). Significant downregulation 
of VEGF-D (when compared to control) was then observed 
at 2 h (P<0.001), 4 h (P<0.001) and 24 h (P<0.001) (Fig. 2C). 
Semi-quantitative analysis and QPCR results showed a trend 
of gradually decreased expression of VEGF-D over the 24 h 
period (Fig. 2C and D).
Protein expression of lymphangiogenic factors and 
markers in the IL-24-treated HECV cells was detected using 
western blot analysis. The results indicate a time-dependent 
downregulation of VEGF-C protein expression by IL-24. 
Levels of VEGF-C protein expression were highest at 0 h with 
decreased expression being detected at 1 and 2 h. Significantly 
low levels of VEGF-C expression (compared to control) were 
detected after 4 h of treatment with IL-24 (P<0.05) (Fig. 3). In 
contrast, levels of VEGF-D and LYVE-1 protein expression 
appeared to decrease in a time-dependent manner (at 1 and 
2 h). After 4 h, however, VEGF-D and LYVE-1 expression 
increased to levels originally detected at time 0 (Fig. 3). 
Further research is required to elucidate whether downregula-
tion of VEGF-D and LYVE-1 protein expression occurs when 
HECV cells are treated with IL-24 for a longer period of time 
(>4 h).
Figure 2. Effect of IL-24 on expression of VEGF-C and VEGF-D in endothelial cells. (A) Semi-quantitative analysis of conventional PCR demonstrating the 
effect of IL-24 on the expression of VEGF-C in HECV endothelial cells. Treatment of HECV cells with IL-24 for 24 h resulted in a significantly reduced 
expression of VEGF-C compared to the control; *P≤0.05. (B) Quantitative PCR demonstrating the effect of IL-24 on the expression of VEGF-C in HECV 
endothelial cells. (C) Semi-quantitative analysis of conventional PCR demonstrating the effect of IL-24 on the expression of VEGF-D in HECV endothelial 
cells. Treatment of HECV cells with IL-24 for 1, 4 and 24 h resulted in significantly reduced expression of VEGF-D compared to the control; ***P≤0.001. 
(D) Quantitative PCR demonstrating the effect of IL-24 on the expression of VEGF-D by HECV endothelial cells.
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IL-24 affects in vitro tubule formation and growth of endo-
thelial cells. IL-24 exhibited a concentration-dependent 
inhibition on microtubule formation of HECV endothelial 
cells (Fig. 4). HECV cells that were incubated with normal 
medium showed the longest perimeter length of microtu-
bules. The most profound reduction in tubule formation was 
observed in cells treated with the highest concentrations 
of IL-24 (25 and 250 ng/ml). In the presence of IL-24 at a 
concentration of 250 ng/ml, microtubule formation of HECV 
cells was significantly impaired compared to microtubule 
formation observed when normal medium was used (P<0.001) 
and when serum-free medium was used (P<0.001). In the 
presence of IL-24 at a concentration of 25 ng/ml, microtu-
bule formation of HECV cells was significantly impaired 
compared to microtubule formation in the presence of normal 
medium (P<0.001).
HECV cells incubated with normal medium showed 
relatively high rates of growth between day 1 and day 3. In 
comparison, HECV endothelial cells exposed to IL-24 at 
concentrations of 2.5 and 25 ng/ml showed reduced growth. 
Figure 4. Effect of IL-24 on the ability of HECV endothelial cells to form microtubules. HECV cells were treated with either (A) normal medium as control, 
(B) serum-free medium as control, (C) 2.5 ng/ml IL-24, (D) 25 ng/ml IL-24 or (E) 250 ng/ml IL-24. IL-24 (25 and 250 ng/ml) significantly inhibited tubule 
formation. (F) Quantitative analysis of the perimeter length of the microtubules formed by HECV endothelial cells treated with IL-24. IL-24 (at a concen-
tration of 250 ng/ml) significantly inhibited the formation of microtubules compared to serum-free medium and normal medium; ***P≤0.001. IL-24 (at a 
concentration of 25 ng/ml) significantly inhibited the formation of microtubules compared to the normal medium;***P≤0.001.
Figure 3. Western blotting demonstrating the effect of IL-24 on protein expression of VEGF-C, VEGF-D and LYVE-1 in HECV endothelial cells. 
(A) Treatment of HECV cells with IL-24 caused significant downregulation of VEGF-C expression after 4 h compared to the control; *P≤0.05. (B-D) Shown 
are quantification of the protein bands normalised against the corresponding loading control.
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The growth rate observed at day 3 was significantly reduced 
(P<0.05) compared to the control when HECV endothelial 
cells were incubated with a high concentration of IL-24 
(250 ng/ml) (Fig. 5).
Discussion
Results obtained in previous studies suggest a link between 
loss of IL-24 and increased likelihood of cancer invasion and 
metastasis particularly in breast cancer (14). IL-24 exerts its 
effects via IL-22R, a cell surface tyrosine kinase receptor. The 
present study attempted to ascertain whether loss of IL-24 
or IL-22R is associated with increased levels of expression 
of lymphangiogenic markers and factors in a large cohort of 
women with breast cancer.
Low expression levels of IL-24 have been found to be 
associated with significantly higher levels of expression 
of the lymphangiogenic markers podoplanin (P<0.05) and 
LYVE-1 (P<0.05), and low levels of expression of IL-22R were 
associated with significantly increased levels of expression of 
LYVE-1 (P<0.05). In addition, breast cancer tissue samples 
were immunohistochemically stained for lymphangiogenic 
factors and markers and IL-24. Within the tissue samples, 
cancer cells and endothelial cells stained strongly for VEGF-C 
and VEGF-D, whereas endothelial cells dislayed a strong 
positivity for Prox-1 and podoplanin. The tissue samples that 
stained strongly for lymphangiogenic factors and markers 
stained very weakly for IL-24. High levels of expression of 
lymphangiogenic markers and factors found within the tissue 
samples may indicate a high density of lymphatic capillaries 
draining the tumour and this may be linked to reduced levels 
of expression of IL-24. What remains unclear is whether IL-24 
has a role in inhibiting the process of lymphangiogenesis of 
tumours thereby reducing the density of lymphatic capillaries 
draining the primary cancer and preventing the dissemination 
of malignant cells to regional lymph nodes.
A number of in vitro assays were carried out to investigate 
the role of IL-24 in reducing lymphangiogenesis. Results 
obtained during the present study suggest that IL-24 acts 
in a time-dependent manner to reduce mRNA expression 
of lymphangiogenic factors VEGF-C and VEGF-D and 
the lymphangiogenic marker Prox-1. Within 24 h of treat-
ment of cells with IL-24, downregulation in the mRNA 
levels of lymphangiogenic factor and marker were detected. 
Downregulation of protein expression of VEGF-C was 
detected after cells were treated with IL-24 for 4 h. In addi-
tion, IL-24 had a significant effect on microtubule formation 
and growth of HECV cells.
The mechanism by which IL-24 exerts anti-lymphan-
giogenic activity is yet to be fully elucidated. Previous 
studies suggest that IL-24 operates through interaction with 
IL-20R1/IL-20R2 or IL-22R1/IL-20R2 heterodimers (15,16). 
Receptor activation is associated with activation of Janus 
activated kinase (JAK)/signal transducers and activators of 
transcription (STAT) signalling. Ramesh et al (17) report that 
inhibition of microtubule formation is mediated by the inter-
action of IL-24 with IL-22R1 resulting in the activation of 
STAT-3. STAT proteins are important in cytokine signalling 
pathways. Al-Rawi and Jiang (2) suggested that stimulation of 
VEGFR-3 results in strong activation of STAT-3. It is possible 
therefore that the regulation of VEGFR-3 signalling (and 
lymphangiogenesis) can be controlled by other cytokines such 
as IL-24, although this requires further investigation.
In conclusion, IL-24 significantly inhibits growth and 
microtubule formation of endothelial cells in vitro and 
downregulates the expression of some lymphangiogenic 
factors and markers. By modifying the ability of endothelial 
cells to function normally, IL-24 may act to impair lymphan-
giogenesis. In addition to the reduced expression of IL-24 and 
IL-22R in breast cancer, this is also correlated with increased 
expression of specific lymphangiogenic factors and markers. 
This suggests that IL-24 plays a role in vivo to suppress 
tumour lymphangiogenesis thereby reducing the likelihood of 
cancer metastasis via the lymphatic route. Further research is 
however required to fully elucidate the mechanisms by which 
IL-24 inhibits lymphangiogenesis.
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